Cancer Immunotherapy Market to Reach $9 Billion Across the World by 2022

Nov 05, 2015, 09:15 ET from RnRMarketResearch

PUNE, India, November 5, 2015 /PRNewswire/ --

This report "Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, And Adoptive T-Cell Therapies" focuses on the rising potential for the newest and most promising of cancer treatments: cancer immunotherapy. Cancer immunotherapy was once just a dream in the minds of physicians, clinicians and patients, but only recently (2010s era) has it actually been within reasonable reach. Cancer Immunotherapy covers three principle therapies that have been in the works for cancer patients are immune checkpoint inhibitors, cancer vaccines and adoptive T-cell therapies.

Complete report on Cancer Immunotherapy market by immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies spread across 141 pages providing 18 tables and 6 figures is available at http://www.rnrmarketresearch.com/cancer-immunotherapy-immune-checkpoint-inhibitors-cancer-vaccines-and-adoptive-t-cell-therapies-market-report.html.

The report is coupled with an in-depth introduction and history as well as with data for market outlook. Also featured in this report are exclusive interviews with three high-end professors, researchers and CEOs:

  1. Adil Daud, MD, Clinical Professor, Department of Medicine (Hematology/Oncology), University of California at San Francisco (UCSF); Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center.
  2. Matthew Lehman, Chief Executive Officer, Prima BioMed (a therapeutic cancer vaccine company with headquarters in Sydney, Australia).
  3. Marcela Maus, MD, PhD, the Director of Translational Medicine and Early Clinical Development, Translational Research Program, Abramson Cancer Center, University of Pennsylvania in Philadelphia.

Furthermore, the reports also conducted and analyzed survey data representing a population sample from the R&D industry. This survey depicts market outlook, and portrays industry opinions and perspectives.

The great majority of the excitement the immuno-oncology field is due to the development of novel immune checkpoint inhibitors. For example, in a March 24, 2014 FierceBiotech article (based on a Wall Street Journal analysis), analysts predicted that the anti-PD-1 agents nivolumab and Merck's pembrolizumab, as well as the anti-PD-L1 agent MPDL3280A, might be approved by the FDA before the end of 2015. They also projected that the three drugs would peak at about $12.5 billion a year.

Other analysts recently projected that the cancer immunotherapy market will increase to nearly $9 billion across the world's major pharmaceutical markets by 2022. They also projected that taken together, BMS' ipilimumab (Yervoy), BMS/Ono's nivolumab, Merck's pembrolizumab, Genentech/Roche/Chugai's MPDL3280A and MedImmune/AZ's MEDI4736 will dominate the immuno-oncology market and capture an 85% market share in 2022.

Experts in the immuno-oncology market show much less enthusiasm for cancer vaccines than for checkpoint inhibitors. Analysts project that the cancer therapeutic vaccines segment of the market will have sales of $1.2 billion in major pharmaceutical market countries in 2022. However, this projection is based on the prediction that five specific vaccine products will join sipuleucel-T (Dendreon's Provenge) as marketed products by 2022. Order a copy of Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies Market Research Report at http://www.rnrmarketresearch.com/contacts/purchase?rname=247902 .

These five vaccines include two that failed in Phase 3 clinical trials, and which the companies that are developing them are trying to revive. The clinical data on the efficacy of a third vaccine is still too preliminary to draw any conclusions. Given these factors, and other uncertainties such as manufacturing difficulties for personalized dendritic vaccines, the degree of accuracy of any projections for the cancer vaccine market is likely to be very low. It is a safe bet, however, that the size of the cancer vaccine market will not approach that of the checkpoint inhibitor market by the 2020-2022 period.

In conclusion, immuno-oncology is expected to be a game-changing approach to treating cancer. It may well constitute a new mode of cancer treatment, alongside surgery, chemotherapy, and radiation therapy. Immunotherapies may eventually be used in as many as 60% of cases of advanced cancer, and are likely to see their first applications in melanoma, NSCLC, and B-cell malignancies. Either alone or in combination therapies, immunotherapies may produce long-term remissions or even cures for cancers that have been uniformly fatal until very recently. Thus immuno-oncology is an important and rapidly emerging field, which deserves the attention it has been receiving in recent years.

Explore more reports on cancer therapeutics market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics.

About Us: 

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us:

G+ / Google Plus: https://plus.google.com/u/0/104156468549256253075/
Twitter: https://twitter.com/RnRMR
Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345
RSS / Feeds: http://www.rnrmarketresearch.com/feed

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@rnrmarketresearch.com


SOURCE RnRMarketResearch